Renaissance Technologies (RenTech)'s ANIK Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 515,717 shares of Anika Therapeutics, Inc. (ANIK) worth $4.96 M, representing 0.01% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 51 quarters.
Based on 13F filings since 2013, Renaissance Technologies (RenTech) has maintained a long-term strategic position in ANIK, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2016, adding 187,400 shares. Largest reduction occurred in Q2 2017, reducing 108,200 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Anika Therapeutics (ANIK) Holding Value Over Time
Track share changes against reported price movement
Quarterly Anika Therapeutics (ANIK) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -17,300 | Reduce 3.25% | 515,717 | $9.61 |
| Q3 2025 | +5,800 | Add 1.10% | 533,017 | $9.40 |
| Q2 2025 | -1,400 | Reduce 0.26% | 527,217 | $10.58 |
| Q1 2025 | +100 | Add 0.02% | 528,617 | $15.03 |
| Q4 2024 | -45,712 | Reduce 7.96% | 528,517 | $16.46 |
| Q3 2024 | -24,000 | Reduce 4.01% | 574,229 | $24.70 |
| Q2 2024 | +38,412 | Add 6.86% | 598,229 | $25.33 |
| Q1 2024 | -4,512 | Reduce 0.80% | 559,817 | $25.40 |
| Q4 2023 | -24,300 | Reduce 4.13% | 564,329 | $22.66 |
| Q3 2023 | -44,600 | Reduce 7.04% | 588,629 | $18.63 |
| Q2 2023 | +57,812 | Add 10.05% | 633,229 | $0.03 |
| Q1 2023 | -20,112 | Reduce 3.38% | 575,417 | $0.03 |
| Q4 2022 | -40,988 | Reduce 6.44% | 595,529 | $0.03 |
| Q3 2022 | -69,300 | Reduce 9.82% | 636,517 | $23.80 |
| Q2 2022 | +29,600 | Add 4.38% | 705,817 | $22.32 |
| Q1 2022 | -7,200 | Reduce 1.05% | 676,217 | $25.11 |
| Q4 2021 | -20,600 | Reduce 2.93% | 683,417 | $35.83 |
| Q3 2021 | -14,700 | Reduce 2.05% | 704,017 | $42.56 |
| Q2 2021 | -26,300 | Reduce 3.53% | 718,717 | $43.29 |
| Q1 2021 | -64,100 | Reduce 7.92% | 745,017 | $40.79 |
| Q4 2020 | -27,400 | Reduce 3.28% | 809,117 | $45.26 |
| Q3 2020 | +1,600 | Add 0.19% | 836,517 | $35.39 |
| Q2 2020 | +87,088 | Add 11.65% | 834,917 | $37.73 |
| Q1 2020 | +162,700 | Add 27.81% | 747,829 | $28.91 |
| Q4 2019 | +102,207 | Add 21.16% | 585,129 | $51.85 |
| Q3 2019 | +38,700 | Add 8.71% | 482,922 | $54.89 |
| Q2 2019 | +78,812 | Add 21.57% | 444,222 | $40.62 |
| Q1 2019 | +102,277 | Add 38.87% | 365,410 | $30.24 |
| Q4 2018 | -6,993 | Reduce 2.59% | 263,133 | $33.61 |
| Q3 2018 | -47,374 | Reduce 14.92% | 270,126 | $42.18 |
| Q2 2018 | +115,400 | Add 57.10% | 317,500 | $32.00 |
| Q1 2018 | +92,400 | Add 84.23% | 202,100 | $49.72 |
| Q4 2017 | -5,000 | Reduce 4.36% | 109,700 | $53.91 |
| Q3 2017 | -30,200 | Reduce 20.84% | 114,700 | $58.00 |
| Q2 2017 | -108,200 | Reduce 42.75% | 144,900 | $49.34 |
| Q1 2017 | +86,300 | Add 51.74% | 253,100 | $43.44 |
| Q4 2016 | -40,900 | Reduce 19.69% | 166,800 | $48.96 |
| Q3 2016 | -63,400 | Reduce 23.39% | 207,700 | $47.85 |
| Q2 2016 | -29,300 | Reduce 9.75% | 271,100 | $53.65 |
| Q1 2016 | +187,400 | Add 165.84% | 300,400 | $44.72 |
| Q4 2015 | +59,400 | Add 110.82% | 113,000 | $38.16 |
| Q3 2015 | -63,600 | Reduce 54.27% | 53,600 | $31.83 |
| Q2 2015 | +4,700 | Add 4.18% | 117,200 | $33.03 |
| Q1 2015 | -100,300 | Reduce 47.13% | 112,500 | $41.17 |
| Q4 2014 | -57,800 | Reduce 21.36% | 212,800 | $40.74 |
| Q3 2014 | -96,800 | Reduce 26.35% | 270,600 | $36.66 |
| Q2 2014 | -75,000 | Reduce 16.95% | 367,400 | $46.33 |
| Q1 2014 | +45,600 | Add 11.49% | 442,400 | $41.10 |
| Q4 2013 | -5,300 | Reduce 1.32% | 396,800 | $38.16 |
| Q3 2013 | +31,397 | Add 8.47% | 402,100 | $23.89 |
| Q2 2013 | +370,703 | Add 0.00% | 370,703 | $17.00 |
Renaissance Technologies (RenTech)'s Anika Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Anika Therapeutics, Inc. (ANIK) in Q2 2013, acquiring 370,703 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Anika Therapeutics, Inc. (ANIK) for 51 quarters since Q2 2013.
Renaissance Technologies (RenTech)'s largest addition to Anika Therapeutics, Inc. (ANIK) was in Q2 2013, adding 370,703 shares worth $6.3 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 515,717 shares of Anika Therapeutics, Inc. (ANIK), valued at approximately $4.96 M.
As of the Q4 2025 filing, Anika Therapeutics, Inc. (ANIK) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Anika Therapeutics, Inc. (ANIK) was 836,517 shares, as reported at the end of Q3 2020.